Multiscale Interoceptive Medicine and Psychedelic Mechanisms: Implications for Neuroimmune Research

Multiscale Interoceptive Medicine: A Unified Model for Disease

A 2026 monograph published in OpenAlex (source) proposes Multiscale Interoceptive Medicine, a formal model uniting central nervous system (CNS) regulation with systemic autoimmune and oncological disease. This framework models the human body as a hierarchy of coupled systems—ranging from individual cells to organ networks and the CNS—each interacting through predictive processing and active inference. The model's central claim is that the right anterior and posterior insular cortex, in concert with the Default Mode Network (DMN), Central Executive Network (CEN), and other key brain and autonomic structures, acts as a master regulatory switch synchronizing psychiatric, immune, and oncological health.

This approach challenges the traditional compartmentalization of medicine—psychiatry, immunology, oncology—by positing a shared mechanism for comorbidities such as anhedonic burnout, autoimmune disorders, and early-onset cancers, especially in adults under 50. The model is formalized mathematically, using non-equilibrium statistical mechanics and active inference to describe how disruptions in central prediction and interoceptive processing can cascade into peripheral cellular dysfunction.

Mechanistic Overlap with Psychedelic Hypotheses

The monograph does not directly address psychedelic compounds, but its focus on insular cortex, DMN, and network-level regulation overlaps with leading mechanistic theories of psychedelic action. Psychedelics such as psilocybin, LSD, and MDMA are hypothesized to modulate large-scale brain networks, including the DMN and insular cortex, which are implicated in interoceptive awareness and the integration of bodily and emotional states.

Of particular note, the model formalizes how chronic disruption of the insular-executive switch can propagate downward to alter circadian rhythms, gap junction connectivity, and immune cell function—mechanisms increasingly speculated to underlie the therapeutic and adverse effects of psychedelic interventions. For example, the monograph's mathematical treatment of allostatic prediction error and its impact on network synchronization offers a quantitative framework that could be directly tested in future psychedelic neuroimaging and immunology studies.

Policy and Research Implications

While the model is theoretical, its systems-level approach may inform the design of future clinical trials and basic research investigating the neuroimmune effects of psychedelics. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly require mechanistic justification for novel psychiatric and immunomodulatory therapies. The formalism presented here could help bridge the gap between observed clinical effects and underlying biological mechanisms, potentially supporting more robust trial designs and biomarker development.

For researchers, the model suggests new experimental paradigms: for instance, longitudinal studies measuring insular cortex activity, DMN connectivity, and peripheral immune markers before and after psychedelic administration. It also highlights the need for interdisciplinary collaboration across psychiatry, immunology, oncology, and computational neuroscience to test the model's predictions and refine its clinical relevance.

• Concrete insight: The model's use of coupled Markov blankets and active inference provides a testable mathematical foundation for the hypothesis that psychedelics may restore network-level synchrony and downstream immune regulation—a step beyond descriptive or correlational accounts common in current literature.

Risks, Limitations, and Unknowns

The immediate clinical and regulatory impact of this monograph is limited. The model is highly formal and not yet validated in large-scale human studies. There is a risk of overextending theoretical frameworks without empirical support, particularly when linking psychiatric network dynamics to complex systemic diseases such as cancer or autoimmunity. Furthermore, the translation of these insights into actionable clinical interventions—psychedelic or otherwise—remains speculative until mechanistic predictions are confirmed in controlled settings.

Another challenge is the potential for reductionism: while the model unifies disparate disease domains, it may underappreciate the role of environmental, social, and genetic factors that modulate disease risk and treatment response. The complexity of human neuroimmune interactions means that any single model, however formal, will require iterative refinement and validation across diverse populations and disease states.

Outlook: Toward Integrative Neuroimmune Trials

The publication of Multiscale Interoceptive Medicine marks a significant step toward a unified theory of psychiatric and systemic disease, with implications for the future of psychedelic research. The next phase will require interdisciplinary trials that integrate neuroimaging, immunology, and computational modeling to test the model's predictions—particularly regarding the modulation of insular cortex and DMN dynamics by psychedelic compounds.

For the field, this work underscores the importance of formal, testable models in bridging basic neuroscience and clinical application. As psychedelic-assisted therapies move through late-phase clinical trials and regulatory review, mechanistic clarity will be essential for both efficacy claims and safety monitoring. The framework outlined here offers a roadmap, but its true value will depend on empirical validation and thoughtful integration with existing clinical and regulatory standards.

How we research: This article was written and reviewed by Dr. Alex M. Reynolds, PhD (Neuroscience, Systems Medicine), on 2026-10-27. Primary source: OpenAlex preprint.